Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study

Jundong Huang, Sihan Deng, Ji Li, Yan Tang, Fangfen Liu, Yu Liu, Shijia Rao, Wei Shi, Jundong Huang, Sihan Deng, Ji Li, Yan Tang, Fangfen Liu, Yu Liu, Shijia Rao, Wei Shi

Abstract

Several non-randomized clinical trials and retrospective studies have demonstrated encouraging efficacy and well-tolerated safety of tofacitinib in the treatment of alopecia areata. However, there are scarce data on a large cohort of patients with alopecia areata in long-term real-world practice. This single-centre, retrospective, observational cohort study included 126 patients with alopecia areata treated with tofacitinib between February 2021 and December 2022. The aims of this study are to evaluate drug survival, effectiveness and safety of tofacitinib for treatment of alopecia areata, and to identify potential factors influencing long-term outcomes. Median duration of treatment was 23.00 (interquartile range (IQR) 15.00, 47.25) weeks. Median all-cause survival time of 126 patients treated with tofacitinib was 44 weeks (95% confidence interval (95% CI) 36.3, 51.7), and the all-cause drug retention rate at 12 weeks, 24 weeks and 48 weeks were 90.0%, 66.4% and 42.3%, respectively. The most common reason for discontinuation was complete remission/satisfaction. A total of 80 patients treated with tofacitinib for over 6 months were included in the efficacy analysis, the overall complete response rate at 24 weeks was 33.8% (27/80). No life-threatening serious adverse events occurred. Sex is an independent risk factor in predicting patient outcomes. This real-world study confirmed the high effectiveness and acceptable safety profile of tofacitinib in alopecia areata, with a satisfactory drug survival rate, and provides supporting data for the clinical application of tofacitinib in Chinese patients with alopecia areata.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Study flow chart.
Fig. 2
Fig. 2
Kaplan–Meier plot of drug survival for tofacitinib in patients with alopecia areata (n = 126). (a) Curves split for different reasons of discontinuation. (b) All-cause drug survival rate curves of the general group and the refractory group.

References

    1. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 366: 1515–1525.
    1. Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, et al. . Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol 2023; 159: 411–418.
    1. Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. . Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 78: 1–12.
    1. Lensing M, Jabbari A. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata. Front Immunol 2022; 13: 955035.
    1. Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 2017; 76: 736–744.
    1. Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 2017; 76: 22–28.
    1. Sanchez-Diaz M, Diaz-Calvillo P, Rodriguez-Pozo JA, Tercedor-Sánchez J, Cantudo-Cuenca MR, Molina-Leyva A, et al. . Tofacitinib for treatment of alopecia areata: real-world evidence and factors associated with therapeutic response. Acta Derm Venereol 2022; 102: adv00736.
    1. Park HS, Kim MW, Lee JS, Yoon HS, Huh CH, Kwon O, et al. . Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J Am Acad Dermatol 2017; 77: 978–980.
    1. AlMarzoug A, AlOrainy M, AlTawil L, AlHayaza G, AlAnazi R, AlIssa A, et al. . Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population. Int J Dermatol 2022; 61: 886–894.
    1. King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. . Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet 2023; 401: 1518–1529.
    1. King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. . Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687–1699.
    1. King BA, Craiglow BG. Janus kinase inhibitors for alopecia areata. J Am Acad Dermatol 2023; 89: S29–s32.
    1. Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. . Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509–519.
    1. Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34: 192–201.
    1. Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, et al. . Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2021; 80: 71–87.
    1. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. . Alopecia areata investigational assessment guidelines – Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004; 51: 440–447.
    1. Taneja N, Gupta S. Apremilast is efficacious in refractory alopecia areata. J Dermatolog Treat 2020; 31: 727–729.
    1. van den Reek J, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, et al. . Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol 2015; 135: 1–5.
    1. Jung JY, Lee E, Kim JW, Suh CH, Kim HA. Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry. Clin Exp Rheumatol 2023; 41: 1034–1041.
    1. Zhang W, Li X, Chen B, Zhang J, Torres-Culala KMT, Zhou C. Oral tofacitinib and systemic corticosteroids, alone or in combination, in patients with moderate-to-severe alopecia areata: a retrospective study. Front Med (Lausanne) 2022; 9: 891434.
    1. Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, et al. . An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol 2018; 138: 1539–1545.
    1. Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol 2021; 61: 403–423.
    1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16: 626–638.
    1. Sandborn WJ, Su C, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 377: 496–497.
    1. Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, et al. . Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 2021; 398: 1984–1996.
    1. Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. . Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2021; 80: 1004–1013.
    1. Taneja V, El-Dallal M, Haq Z, Tripathi K, Systrom HK, Wang LF, et al. . Effectiveness and safety of tofacitinib for ulcerative colitis: systematic review and meta-analysis. J Clin Gastroenterol 2022; 56: e323–e333.
    1. Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol 2022; 18: 301–304.
    1. Ozdede A, Yazıcı H. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386: 1766.
    1. Yan D, Fan H, Chen M, Xia L, Wang S, Dong W, et al. . The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies. Front Pharmacol 2022; 13: 950450.
    1. Akada H, Akada S, Hutchison RE, Sakamoto K, Wagner KU, Mohi G. Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells 2014; 32: 1878–1889.
    1. Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. J Hematol Oncol 2013; 6: 65.
    1. Hao XR, Cao DL, Hu YW, Li XX, Liu XH, Xiao J, et al. . IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis 2009; 203: 417–428.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi